A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Agents
  • Carcinoma, Squamous Cell
  • Esophageal Neoplasms
  • Quinazolines
  • Receptor, Epidermal Growth Factor

abstract

  • Erlotinib had limited activity in patients with esophageal cancer, and responses and some protracted stable disease were observed in those with squamous cell carcinoma. Efficacy according to EGFR status could not be assessed given the rarity of EGFR-negative tumors. The current results indicated that further evaluation of this agent in squamous cell carcinoma is warranted. Cancer 2011. © 2010 American Cancer Society.

publication date

  • April 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3116987

Digital Object Identifier (DOI)

  • 10.1002/cncr.25602

PubMed ID

  • 21425140

Additional Document Info

start page

  • 1409

end page

  • 14

volume

  • 117

number

  • 7